Navigation Links
Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
Date:4/4/2011

MOUNTAIN VIEW, Calif., April 4, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced long-term data that demonstrated patients treated with the investigational drug QNEXA® for two years showed reductions in blood pressure and the use of antihypertensive medications as well as improvements in lipid levels following significant reductions in weight loss as compared to those in the placebo group over two years.

The data – additional results from the SEQUEL study – were presented Sunday at the 60th Annual Scientific Meeting of The American College of Cardiology by Michael Davidson, M.D., clinical professor and director of preventive cardiology at The University of Chicago.

Specific results are as follows:

  • Patients on QNEXA had significant reductions in weight loss as compared to those in the placebo group over two years. Least-squares mean percent weight loss at week 108 was -9.3% and -10.5%, respectively, for the mid and top dose as compared to -1.8% for the placebo group.
  • Overall, patients taking QNEXA showed a significant reduction in the number of antihypertensive medications they required as compared to those taking a placebo over two years of treatment.
  • Specifically, patients with hypertension at the beginning of the study taking QNEXA mid and top dose showed a significant reduction in the number of antihypertensive medications they required of -9.8% and -18.9%, respectively, while patients taking a placebo showed a net increase of +4.2%.
  • Dyslipidemic patients at baseline treated with the mid and top dose of QNEXA had decreases in triglycerides of -25.9% and -26.3%, respectively, as compared to -14.3% for the placebo group.
  • Dyslipidemic patients at baseline treated with the mid and top dose of QNEXA had improvements in HDL-C of +11.4% and +16.7%, respectively, as c
    '/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant
2. Medizone Internationals Mass-Market Sterilization Technology to be Produced by Canadian Medical Device Heavyweights
3. The Spatz Adjustable Balloon System® for Weight Loss Becomes the First Intragastric Balloon to Receive Regulatory Approval for 1 Year Implantation Time
4. Results of Innovative Clinical Study Show New Combination for Weight Loss Success
5. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
6. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year
7. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at 52 Weeks
8. The Results are in: Users of BodyMedias Wearable Body-Monitoring Technology Lose 3 Times More Weight
9. ReShape Medical Announces Initiation of U.S. Clinical Study for Weight Loss
10. Womens Digital Imaging Using DXA Total Body Fat Analysis to Help Patients in Weight Management and Fitness Programs
11. New Survey Shows Seniors Struggle Under the Weight of Multiple Medication Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at 165 ... the first in Loudoun County to receive ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian of ... Taylor , are avid scuba divers. "As altitude skiers and hikers, ...
(Date:1/14/2014)... January 14, 2014 Equashield ( ... hazardous drugs, today announced that it has achieved ... year.   Equashield,s closed systems reduce ... nurses and other medical professionals who prepare and ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
... 2007 - ImmunoGen, Inc.,(Nasdaq: IMGN), a biopharmaceutical company ... (TAP),technology, today announced that clinical findings for three,different ... are to be,reported at the 43rd American Society ... June 1-5, 2007 in Chicago, IL., Trastuzumab-DM1 (abstract ...
... 2007 - GTx, Inc., (NASDAQ:,GTXI) announced today that ... clinical trial of Ostarine(TM) and from the ongoing ... for the treatment of multiple side effects of ... upcoming 2007,Annual Meeting of the American Society of ...
Cached Medicine Technology:ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 2ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 3GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... 16, 2014) The cause of neuronal death in ... proposes that neurons may be mistaken for foreign invaders ... to the way autoimmune diseases like type I diabetes, ... The study was published April 16, 2014, in ... likely controversial, idea in Parkinson,s disease; but if true, ...
(Date:4/17/2014)... international team led by researchers at UC Davis has ... a key role in cell division, also boosts the ... first time the complex has been shown to perform ... an excellent target to control cellular energy production, potentially ... published online today in the journal Developmental Cell ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... get the blues during the course of the winter and ... far more difficult to overcome the seasonal affective disorder (SAD), ... ,Those who suffer from SAD overeat, sleep ... irritability and depression and develop an aversion to social interactions. ...
... associated with several alleged miscarriages of justice has been ... decision has been hailed as one to preserve public ... officials in Saskatchewan have voted to curtail practicing privileges ... Smith. ,Smith had been granted temporary ...
... are reporting that the traditional method of assessing the ... the danger //of missing one-third of women who are ... ,Roger Blumenthal, M.D., an associate professor and ... Johns Hopkins University School of Medicine and its Heart ...
... University of Chicago have announced findings of archeological evidence that ... leading to the destruction of a city. Clemens Reichel, a ... was conducted was a war zone. Artifacts from daily life ... at the Iraqi border. ,The findings prove ...
... milk is so there is study in Australia ... with nutraceutical, pharmaceutical and agrochemical potential.// ... Queensland's Institute for Molecular Bioscience (IMB) and the ... has teamed up with MG Nutritionals for the ...
... Woo Suk the cloning pioneer of South Korea is defending ... editors of Science magazine in Washington to retract his work.//, ... magazine, Donald Kennedy said that Hwang would have 'days or ... his bid to retract a pioneering article that held out ...
Cached Medicine News:Health News:Calcium Levels Could Indicate Future Heart Disease Risk 2Health News:Excavations Reveal Clues Of Early Warfare 2Health News:Scientist Calls Upon Media To Retract His Work 2
Used for drainage and navigation of a tortuous ureter. The tapered tip eases placement as there are no edges to interfere with the ureteral orifice. Supplied sterile in peel-open packages. Intended f...
... The grasper wires are constructed of stainless ... of Delta Wire creates a three-prong grasper ... superior mass of the Delta Wire creates ... permits greater radial dilation in the ureter. ...
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
... the USA Series, ACMITM introduces the latest ... II -- the longest cystourethroscope working length ... offers the components you need for every ... System II Cystourethroscopes provide all of the ...
Medicine Products: